Homepage Top Section2

Through the early-stage trial called DUET-3, Xencor will assess the safety and tolerability of XmAb23104 in an estimated 144 patients with selected advanced solid tumors. The participants will

The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Based in San Diego of California, Pharmapace has expertise in offering biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will be

Dengvaxia is said to be the first FDA-approved vaccine to prevent dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people aged between

With over 250 employees, the San Diego research center will focus on leveraging specialized drug discovery technologies, as well as advancing discovery research in gastroenterology and neuroscience, said

The collaboration will combine the genomics, chemistry and clinical data of AstraZeneca with the target identification platform and biomedical knowledge graph of BenevolentAI. BenevolentAI’s biomedical knowledge graph is

The company has submitted a new drug application (NDA) to the FDA for two-drug regimen to treat HIV-1 infection in adults whose viral load is suppressed and who

Luspatercept is an erythroid maturation agent (EMA), which has been designed to regulate late-stage red blood cell maturation. The drug is being jointly developed by Acceleron and Celgene

Stellar-3 is a randomized, double-blind and placebo-controlled trial, which assessed the safety and efficacy of selonsertib in patients with bridging fibrosis (F3) due to NASH. According to the